Cáncer de próstata metastásico hormono-sensible : ¿Cómo deberíamos tratar a nuestros pacientes?

Hormone-sensitive metastatic prostate cancer: How should we treat our patients?

Contenido principal del artículo

Ray Manneh Kopp

Descargas

Los datos de descargas todavía no están disponibles.

Detalles del artículo

Biografía del autor/a (VER)

Ray Manneh Kopp, Sociedad de Oncología y Hematología del Cesar, Valledupar - Colombia

Ray Manneh Kopp, MD

Oncología Clínica. Oncología Genitourinaria.

Sociedad de Oncología y Hematología del Cesar.

Grupo de Oncología Genitourinaria de Colombia (GOGUC).   

Palabras clave:

Referencias (VER)

Francini E, Gray K, Xie W. Time of metastatic disease presentation and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC). Prostate Sep;78 (12):889-895. https://doi.org/10.1002/pros.23645

Gravis G, Boher J-M, Chen Y-H. Burden of metastatic castrate naive prostate cancer patients, to identify men more likely to benefit from early docetaxel: further analyses of CHAARTED and GETUG_AFU15 studies. Eur Urol Jun;73 (6):847-855. https://dx.doi.org/10.1016%2Fj.eururo.2018.02.001

Sweeney C, Chen Y-H, Carducci M. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med 2015; 373:737-746. https://doi.org/10.1200/jco.2017.75.3657

James N, Sydes M, Clarke N, Mason M, Dearnaley D, Spears M, et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomized controlled trial. Lancet.2016 Mar 19;387 (10024): 1163-77. https://doi.org/10.1016/s0140-6736(15)01037

Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev B, et al. Abiraterone plus prednisone in metastatic castration-sensitive prostate cancer. N Engl J Med 2017. Jul 27;377(4):352-360. https://doi.org/10.1056/nejmoa1704174

James N, de Bono J, Spears M. Abiraterone for prostate cancer not previously treated with hormone therapy. N Engl J Med. 2017 Jul 27;377(4):338-35. https://goi.org/10.1056/NEJMoa1702900

Parker C, James N, Brawley C. Clarke N, Hoyle A, Ali A, et al. Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomized controlled phase 3 trial. Lancet 2018 Dec 1;392 (10162):2353-2366. https://doi.org/10.1016/s0140-6736(18)32486-3

Amstrong A, Szmulewitz R, Petrylak D, Holzbeierlein J, Villers A, Azad A, et al. ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide of placebo in men with metastatic hormonse-sensitive prostate cancer. J Cllin Oncol. 2019 Nov 10;37(32): 2974-2986. https://doi.org/10.1200/jco.19.00799

Davis I, Martin A, Stockler M, Begbie S, Chi KN, Chowdhury S, et al. Enzalutamide with standard first-line therapy in metastatic prostate cancer. N Engl J Med. 2019 Jul 11;381(2);121-131. https://doi.org/10.1056/nejmoa1903835

Chi K, Agarwal N, Bjartell A, Chung BH, Pereira de Santana Gomes AJ, Given R, et al. Apalutamide for metastatic, castration-sensitive prostate cancer. N Engl J Med 2019 Jul 4;381(1):13-24. https://doi.org/10.1056/nejmoa1903307

Contadores